Avantax Advisory Services Inc. Sells 445 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Avantax Advisory Services Inc. cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,321 shares of the biopharmaceutical company’s stock after selling 445 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Halozyme Therapeutics were worth $595,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Isthmus Partners LLC raised its stake in Halozyme Therapeutics by 2.5% during the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 169 shares during the last quarter. OneDigital Investment Advisors LLC raised its stake in Halozyme Therapeutics by 1.7% during the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 175 shares during the last quarter. Park Place Capital Corp raised its stake in Halozyme Therapeutics by 20.1% during the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 182 shares during the last quarter. Xponance Inc. raised its stake in Halozyme Therapeutics by 1.1% during the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 198 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 207 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $41,403,763.17. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 60,000 shares of company stock worth $3,262,400 in the last three months. 2.90% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Up 1.6%

Halozyme Therapeutics stock opened at $59.99 on Tuesday. The stock has a market cap of $7.39 billion, a PE ratio of 15.95, a price-to-earnings-growth ratio of 0.39 and a beta of 1.17. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.50. The stock has a fifty day moving average of $55.40 and a 200 day moving average of $57.78.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analysts’ expectations of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. Halozyme Therapeutics’s revenue for the quarter was up 35.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.79 earnings per share. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on HALO. Leerink Partners cut Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price objective for the company. in a research note on Tuesday, May 13th. HC Wainwright restated a “buy” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Morgan Stanley cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $73.00 to $62.00 in a research note on Wednesday, May 14th. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price target for the company. Finally, Leerink Partnrs cut Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 13th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $62.70.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.